Sartorius Stedim Biotech to acquire Danaher’s select businesses for $750m
Sartorius Stedim Biotech (SSB) has agreed to acquire certain assets of Danaher’s Life Science portfolio for a consideration of approximately $750m in cash, subject to the closing conditions.